Sector News

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

November 27, 2020
Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

Carlos Alban plans to retire as vice chairman and chief commercial officer at the end of the first quarter 2021, AbbVie disclosed Thursday. Taking his place will be Jeffrey Stewart, currently AbbVie’s head of U.S. commercial operations.

Both are longtime AbbVie employees. Alban joined the company 34 years ago, back when it was still part of Abbott, and advanced to the CCO title amid an executive team consolidation in late 2018. At the time, he was named as one of four senior managers reporting directly to CEO Richard Gonzalez.

Stewart joined Abbott in 1992 as part of TAP, a former U.S. joint venture Abbott had with Takeda. He was Abbott’s vice president of proprietary pharmaceuticals overseeing the U.S. market—while Alban was the senior VP—when the company spun AbbVie off into a separate pure-pharma play.

Perhaps the most important job in front of Stewart is the gradual transition of AbbVie’s commercial focus from aging megablockbuster Humira to new, growing meds such as psoriasis treatment Skyrizi and rheumatoid arthritis therapy Rinvoq.

So far, the two drugs have not disappointed. In the third quarter, Skyrizi and Rinvoq together brought in $650 million in sales. That put the two meds “well ahead of all comparable launch analogs in their initial indications,” Gonzalez said during an investor’s call a few days ago.

Skyrizi’s $435 million haul and Rinvoq’s $215 million both beat industry watchers’ expectations by double-digit percentages. If they continue on this growth trajectory, the two could easily exceed the $10 billion-by-2025 sales target AbbVie previously set for the medicines, Gonzalez said.

As of Q3, Skyrizi had snagged a 33% U.S. market share among new and switching patients, and Rinvoq about 16% in its indication. The numbers were impressive given that COVID-19 is posing a challenge for promoting newer meds, with dermatology as one of the hardest-hit therapeutic areas as doctor visits lagged.

The launches of Skyrizi and Rinvoq are doing so well that SVB Leerink analyst Geoffrey Porges recently said the pair could drive top- and bottom-line performance for AbbVie for three to four years at least.

AbbVie’s actively expanding the drugs into other lucrative indications, too. It expects approvals next year for Rinvoq in psoriatic arthritis, ankylosing spondylitis and atopic dermatitis, which could by itself add multibillion-dollar revenues at peak, Gonzalez said. It’s also eyeing psoriatic arthritis for Skyrizi and inflammatory bowel disease for both drugs.

The two new launches’ success has AbbVie’s commercial capabilities to thank. Its marketing muscle, especially in immunology, has long been proven with Humira, which is bracing for a U.S. biosimilar attack starting in 2023.

Because of the new launches and the Allergan acquisition, Humira’s share in AbbVie’s revenues has dropped from about 60% to about 40% now, and Porges figured it would fall further to low-30% right before Humira’s patent cliff.

by Angus Liu

Source: fiercepharma.com

1 response to “AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

  • Mitch says:

    Whats up tһis is somewhat of off topic but I
    was ᴡanting to know if ƅlogs use WYSӀWYG editors or if you have to manually code
    with HTⅯL. I’m starting a blog ѕoon Ьut have no coding
    knowledge so I wanted to get guidance from someone with experience.
    Аny help would be greatly appreciated!

    mү web-site – altars

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend